The Effect of Bariatric Surgery on Hepatic Metabolism in Non-Alcoholic Fatty Liver Disease
Launched by HELSINKI UNIVERSITY CENTRAL HOSPITAL · Sep 20, 2022
Trial Information
Current as of July 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Bariatric surgery is one of the few currently available treatment options for non-alcoholic fatty liver disease (NAFLD). In most cases, NAFLD is entirely ameliorated after the surgery but in some individuals, the disease may persist or even progress. The mechanisms underlying the bariatric surgery-mediated resolution of NAFLD and the heterogeneity in the response remain poorly understood. In this study, the investigators will examine the metabolic effects of bariatric surgery-induced resolution of NAFLD. To this end, study subjects who have previously undergone bariatric surgery and metabol...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants must have undergone bariatric surgery and previously participated in a metabolic study in our research group.
- • Participants must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent.
- • Age range from 18-75 years.
- Exclusion Criteria:
- • No claustrophobia or metal implants to allow magnetic resonance spectroscopy.
- • No pregnancy or lactation in women.
About Helsinki University Central Hospital
Helsinki University Central Hospital (HUCH) is a leading academic medical institution in Finland, dedicated to advancing healthcare through innovative research and clinical excellence. As a pivotal sponsor of clinical trials, HUCH integrates cutting-edge medical practices with rigorous scientific inquiry, fostering collaborations between researchers, healthcare professionals, and patients. The hospital is committed to enhancing patient outcomes and contributing to the global body of medical knowledge by conducting high-quality, ethically sound clinical studies across a diverse range of therapeutic areas. With a strong emphasis on education and training, HUCH plays a vital role in shaping the next generation of healthcare leaders and researchers.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Helsinki, , Finland
Patients applied
Trial Officials
Panu K Luukkonen, MD, PhD
Principal Investigator
Helsinki University Central Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials